DK4065176T3 - Kombination af para-aminohippursyre (pah) og radioaktivt mærkede komplekser til behandling af kræft - Google Patents

Kombination af para-aminohippursyre (pah) og radioaktivt mærkede komplekser til behandling af kræft Download PDF

Info

Publication number
DK4065176T3
DK4065176T3 DK21810930.4T DK21810930T DK4065176T3 DK 4065176 T3 DK4065176 T3 DK 4065176T3 DK 21810930 T DK21810930 T DK 21810930T DK 4065176 T3 DK4065176 T3 DK 4065176T3
Authority
DK
Denmark
Prior art keywords
aminohippurous
pah
para
cancer
radio
Prior art date
Application number
DK21810930.4T
Other languages
Danish (da)
English (en)
Inventor
Marian Meckel
Theresa Osl
Konstantin Zhernosekov
Original Assignee
Itm Isotope Tech Munich Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Itm Isotope Tech Munich Se filed Critical Itm Isotope Tech Munich Se
Application granted granted Critical
Publication of DK4065176T3 publication Critical patent/DK4065176T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK21810930.4T 2020-11-05 2021-11-05 Kombination af para-aminohippursyre (pah) og radioaktivt mærkede komplekser til behandling af kræft DK4065176T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2020/081143 WO2022096103A1 (en) 2020-11-05 2020-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
PCT/EP2021/080822 WO2022096673A1 (en) 2020-11-05 2021-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer

Publications (1)

Publication Number Publication Date
DK4065176T3 true DK4065176T3 (da) 2024-01-02

Family

ID=73138835

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21810930.4T DK4065176T3 (da) 2020-11-05 2021-11-05 Kombination af para-aminohippursyre (pah) og radioaktivt mærkede komplekser til behandling af kræft

Country Status (13)

Country Link
US (1) US20230414796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7531707B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230127212A (cg-RX-API-DMAC7.html)
CN (1) CN116981487A (cg-RX-API-DMAC7.html)
AU (1) AU2021375728A1 (cg-RX-API-DMAC7.html)
DK (1) DK4065176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2967379T3 (cg-RX-API-DMAC7.html)
FI (1) FI4065176T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065304T2 (cg-RX-API-DMAC7.html)
PL (1) PL4065176T3 (cg-RX-API-DMAC7.html)
WO (2) WO2022096103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304769B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022007815A1 (tr) * 2022-05-13 2023-11-21 Ege Ueniversitesi Idari Ve Mali Islerdaire Bsk Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t
CN115212322B (zh) * 2022-06-01 2024-01-16 原子高科股份有限公司 一种用于放射性药物制备的冻干药盒及其制备方法
WO2025113628A1 (en) * 2023-11-30 2025-06-05 Full-Life Technologies Hk Limited Sstr receptor targeting radio compounds and uses thereof
EP4763231A1 (en) * 2024-12-20 2026-06-24 ITM Isotope Technologies Munich SE Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176427A (ja) 2004-12-21 2006-07-06 Geno Membrane:Kk エストロン3硫酸トランスポーター活性の阻害剤
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
CA2686933A1 (en) * 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) * 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance

Also Published As

Publication number Publication date
WO2022096103A1 (en) 2022-05-12
FI4065176T3 (fi) 2024-01-18
ZA202304769B (en) 2024-10-30
PL4065176T3 (pl) 2024-03-18
AU2021375728A9 (en) 2024-06-20
CN116981487A (zh) 2023-10-31
JP7531707B2 (ja) 2024-08-09
US20230414796A1 (en) 2023-12-28
CA3171718A1 (en) 2022-05-12
ES2967379T3 (es) 2024-04-30
AU2021375728A1 (en) 2023-06-15
HUE065304T2 (hu) 2024-05-28
EP4065176A1 (en) 2022-10-05
KR20230127212A (ko) 2023-08-31
EP4065176B1 (en) 2023-10-11
JP2023547689A (ja) 2023-11-13
WO2022096673A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
DK4096717T3 (da) Behandling af cancer
DK4181920T3 (da) Kat6-inhibitor og kombinationer til behandling af brystkræft
DK4065585T3 (da) Substituerede makrocykliske forbindelser og relaterede behandlingsfremgangsmåder
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
DK3579848T3 (da) Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
EP3743069C0 (en) BCL-2 PROTEIN-DEGRADING AGENTS FOR CANCER TREATMENT
DK3778592T3 (da) PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3773738T3 (da) Antistof-lægemiddelkonjugater og anvendelser deraf til behandling af cancer
DK3341001T3 (da) Sammensætning og fremgangsmåde til behandling og profylakse af tarminfektion og -inflammation
DK3727130T3 (da) Medicinsk system og fremgangsmåde til fremstilling deraf
DK3609497T3 (da) Niraparib, abirateronacetat og prednison til behandling af prostatakræft
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
DK3755816T3 (da) Fremgangsmåder til påvisning og behandling af prostatacancer
DK4125842T3 (da) Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK4058474T3 (da) Sammensætninger og fremgangsmåder til behandling af egfr-positive kræftformer
DK3886917T3 (da) Kobbernanoklynger, sammensætning omfattende samme og behandling af neurodegenerative sygdomme
EP4493175A4 (en) MIRDAMETINIB TREATMENT
DK4452256T3 (da) Fremgangsmåder til behandling af hjernetumorer og neuroblastomer
IL281845A (en) Combination therapy for the treatment of cancer
EP4440623A4 (en) Polytherapy for the treatment of cancer
IL285155A (en) Metal chelator combination therapy for the treatment of cancer